Gabather

* Phase II clinical trial activated * Cost control is still kept strict * We keep our fair value of SEK 0.06 per share Gabather's first report of 2026 came in close to our estimates, with an EBIT of KSEK -1 052 against our projected KSEK -1 136. The ...

* Approval to initiate the financed TOTEMS study * Patient enrolment imminent Gabather has announced the initiation of the TOTEMS study, a phase II clinical trial evaluating the drug candidate GT-002 in patients with schizophrenia spectrum disorders....

* A directed share issue adds MSEK 4.2 before costs * First patient enrolment expected as next trigger * We keep our fair value of SEK 0.06 per share Gabather has carried out a directed share issue of approximately MSEK 4.2 with participation from several...

* Exercise of warrants and a directed share issue extends runway * Phase II clinical trial expected to start very soon * After dilution, our fair value amounts to SEK 0.06 per share Gabather’s Q4 report showed lower-than-expected costs, primarily due...

CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Västra Hamnen's analyst Jacob Murat.